Application Note

Transdermal Sufentanil Licensing Opportunity

Format: PDF file | Document type: Application Note | Promoted Content

This Application Note has been written by Aveva , and any views and opinions expressed do not necessarily reflect those of www.outsourcing-pharma.com

Transdermal Sufentanil Licensing Opportunity

Aveva's 7-day sufentanil's advanced technology and patient benefits will enable Aveva and its Partner to capture a significant share of the existing $3.9 billion dollar chronic pain market.

Supplier info centre